The partners will evaluate circulating tumor cell-based biomarker panels as potential new tests for use on Ikonisys' Ikoniscope fluorescence microscopy system.
Cardinal Health will offer the device as a standalone product to hospitals and as part of a customizable kit to address blood culture contamination.
The company signed a distribution agreement in Japan for its Idylla products and also initiated a listing of €150 million in unsecured convertible bonds.
JP Morgan noted that it sees potential for new management to "reset the bar" and as such thinks the "worst is in the rearview for Qiagen."
The genetic testing firm is offering approximately 2.3 million shares at $11.25 per share and plans to use the funds for general corporate purposes.
The German molecular diagnostics firm is preparing for its merger with US-based OpGen, which is slated to close in the first quarter of next year.
The firm said that in a first phase of the contract it will focus on further development of its fever test that analyzes immune system gene expression patterns.
The San Diego-based company said that the number of commercial samples received during the quarter grew 66 percent year over year.
The platform retained high sensitivity after exposure to plasma for more than one month, opening up a range of potential diagnostic applications, the researchers said.
The company has seen a sharp rise in test revenues but still struggles with poor stock performance and could soon see new competition for OVA1.